NCT05085561Phase 2Completed

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2025-06-30Actual
Enrollment · participants62Actual
Source updated2026-06-23Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.